Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Alpha-fetoprotein

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    72 result(s) found for: Alpha-fetoprotein. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2009-016475-29 Sponsor Protocol Number: RAD-09 Start Date*: 2010-03-11
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: Treatment of advanced hepatocellular carcinoma (HCC) with portal vein thrombosis by hepatic intra-arterial injection of microspheres loaded with Yttrium-90 (Thera-Sphere)
    Medical condition: advanced hepatocellular carcinoma (HCC) with portal vein thrombosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10024662 LLT
    9.1 10019713 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011884-35 Sponsor Protocol Number: SAKK 77/08 and SASL 29 Start Date*: 2009-12-19
    Sponsor Name:Swiss Group for Clinical Cancer Research
    Full Title: Sorafenib alone or in combination with everolimus in patients with unresectable hepatocellular carcinoma. A randomized multicenter phase II trial.
    Medical condition: Patients with unresectable hepatocellular carcinoma.
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: HU (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2009-009882-33 Sponsor Protocol Number: TE-2009-01 Start Date*: 2010-06-10
    Sponsor Name:St Bartholomew's and The London NHS Trust
    Full Title: A multi-centre phase II study using Carboplatin AUC-10 for metastatic seminoma with IGCCCG good prognosis disease - therapy directed by initial metabolic response on PET-CT [CAR-PET]
    Medical condition: Metastatic seminoma
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-004126-13 Sponsor Protocol Number: CaPture Start Date*: 2020-10-06
    Sponsor Name:University Leipzig
    Full Title: Cabozantinib treatment in a phase II study for patients with hepatocellular carcinoma (HCC) refractory to PD-1 or PD-L1 inhibitors
    Medical condition: Hepatocellular carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000912-34 Sponsor Protocol Number: PR003-CLN-pro001 Start Date*: 2008-05-07
    Sponsor Name:Protherics Development Medicines Ltd
    Full Title: A PHASE 2 STUDY OF THE ANTI-TUMOUR ACTIVITY AND SAFETY OF PROLARIX™ IN HEPATOCELLULAR CARCINOMA (HCC)
    Medical condition: Hepatocellular Carcinoma (HCC)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-001502-10 Sponsor Protocol Number: GCTSK002 Start Date*: 2011-09-28
    Sponsor Name:National Cancer Institute
    Full Title: Phase II study of Everolimus in refractory testicular germ cell cancer.
    Medical condition: refractory metastatic germ cell tumors
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2008-003925-17 Sponsor Protocol Number: HCC-PBMC-GM-CSF Start Date*: 2008-10-20
    Sponsor Name:AZIENDA OSPEDALIERA DI PARMA
    Full Title: Immunotherapy by autologous peripheral blood mononuclear cells and GM-CSF for hepatocellular carcinoma undergoing radiofrequency thermal ablation
    Medical condition: patients with hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059319 Hepatic cancer stage II LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-003977-22 Sponsor Protocol Number: SAKK 77/06 and SASL 23 Start Date*: 2007-10-12
    Sponsor Name:Swiss Group for Clinical Cancer Research (SAKK)
    Full Title: Protocol SAKK 77/06 and SASL 23 Continuous sunitinib treatment in patients with unresectable hepatocellular carcinoma A multicenter phase II trial
    Medical condition: Patients with unresectable hepatocellular carcinoma, localized but surgically unresectable or metastatic
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000452-24 Sponsor Protocol Number: M13-576 Start Date*: 2017-03-27
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinic...
    Medical condition: Hepatitis C Virus
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10019752 Hepatitis C virus (HCV) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-000798-31 Sponsor Protocol Number: NEMA-0027-018 Start Date*: 2007-03-02
    Sponsor Name:Nerviano Medical Sciences S.r.l.
    Full Title: Phase II randomized study of nemorubicin hydrochloride (PNU-152243A) or doxorubicin administered in adult patients with unresectable hepatocellular carcinoma
    Medical condition: Hepatocellular Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-000618-35 Sponsor Protocol Number: M07PGC Start Date*: 2007-11-29
    Sponsor Name:Rigshospitalet
    Full Title: PHASE II TRIAL OF PACLITAXEL, GEMCITABINE AND CISPLATIN IN PATIENTS WITH RELAPSING GERM CELL CANCER AFTER FIRST LINE CHEMOTHERAPY
    Medical condition: · The primary objective of this study is to investigate the combination of cisplatin/gemcitabine/paclitaxel, with respect to progression free survival in patients with germ cell tumours previously...
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Ongoing) DK (Completed) SK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-000739-28 Sponsor Protocol Number: CT-AMT-060-04_(CSL220_1002) Start Date*: 2020-11-19
    Sponsor Name:CSL Behring LLC
    Full Title: A Phase I/IIb extension study assessing the long-term safety and efficacy of an adeno-associated viral vector containing a codon-optimized human factor IX gene (AAV5-hFIX) previously administered t...
    Medical condition: Haemophilia B
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10018939 Haemophilia B (Factor IX) LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Trial now transitioned) DK (Prematurely Ended) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-000731-26 Sponsor Protocol Number: NEMA-0027-017 Start Date*: 2006-03-28
    Sponsor Name:Nerviano Medical Sciences S.r.l.
    Full Title: Nemorubicin hydrochloride (PNU-152243A) administered via intrahepatic artery in combination with cisplatin in adult patients with unresectable hepatocellular carcinoma: Phase II study preceded by d...
    Medical condition: Unresectable hepatocellular carcinoma (HCC)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed) DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-004132-29 Sponsor Protocol Number: Sobi.NTBC-003 Start Date*: 2014-10-15
    Sponsor Name:Swedish Orphan Biovitrum AB (Publ)
    Full Title: An open-label, non-randomized, sequential, multicenter study to evaluate the pharmacokinetics, efficacy and safety of once daily dosing compared to twice daily dosing of Orfadin in patients diagnos...
    Medical condition: hereditary tyrosinemia type 1
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004850 10069462 Tyrosinemia type I LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-008715-26 Sponsor Protocol Number: CA182037 Start Date*: 2009-08-05
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: A Randomized, Double-blind, Multicenter Phase III Study of Brivanib versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Embolization (TACE) in Patients with Unresectable Hepatocellular Carci...
    Medical condition: intermediate stage hepatocellular carcinoma (HCC)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-003073-26 Sponsor Protocol Number: M13-102 Start Date*: 2013-10-22
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatme...
    Medical condition: Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    17.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed) DE (Completed) ES (Completed) HU (Prematurely Ended) AT (Completed) BE (Completed) DK (Completed) PT (Completed) PL (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004305-40 Sponsor Protocol Number: CSL222-3001 Start Date*: 2018-10-12
    Sponsor Name:CSL Behring LLC
    Full Title: Phase III, open-label, single-dose, multi-center multinational trial investigating a serotype 5 adeno-associated viral vector containing the Padua variant of a codon-optimized human factor IX gene ...
    Medical condition: Hemophilia B
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10018939 Haemophilia B (Factor IX) LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Trial now transitioned) GB (GB - no longer in EU/EEA) IE (Trial now transitioned) NL (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) SE (Trial now transitioned) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-010590-20 Sponsor Protocol Number: TMC435-TiDP16-C206 Start Date*: 2009-10-21
    Sponsor Name:Tibotec Pharmaceuticals
    Full Title: A Phase IIb, randomized, double-blind, placebo-controlled trial to investigate the efficacy, tolerability, safety and pharmacokinetics of TMC435 as part of a treatment regimen including PegIFNα-2a ...
    Medical condition: Hepatitis C Virus (HCV)
    Disease: Version SOC Term Classification Code Term Level
    12.0 10019752 Hepatitis C virus (HCV) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) PT (Completed) AT (Completed) GB (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2005-000867-24 Sponsor Protocol Number: ALFR-HC-04 Start Date*: 2005-05-23
    Sponsor Name:Human Genome Sciences, Inc.
    Full Title: A PHASE 2b, RANDOMIZED, MULTI-CENTER, ACTIVE-CONTROLLED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALBUFERON (RECOMBINANT HUMAN ALBUMIN-INTERFERON ALFA FUSION PROTEIN) IN COMBINATION...
    Medical condition: Hepatitis type C chronic
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2005-005507-41 Sponsor Protocol Number: NV18210 Start Date*: 2007-01-28
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Randomized, Multicenter, Double-Blinded, Phase IV Study Evaluating the Efficacy (as measured by Sustained Virological Response) and Safety of 360 µg Induction Dosing of Pegasys in Combination with ...
    Medical condition: genotype 1 chronic hepatitis C infection of high viral titer and baseline body weight greater than or equal to 85 kg
    Disease: Version SOC Term Classification Code Term Level
    8.1 10008912 Chronic hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) NL (Completed) SE (Completed) DE (Completed) BE (Completed) DK (Completed) FR (Completed) GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 03:42:34 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA